ArticleJournal of cellular and molecular medicine2025
Investigating Liquid-Liquid Phase Separation in Lung Adenocarcinoma to Improve Prognostic Accuracy and Treatment Efficacy.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigating Liquid-Liquid Phase Separation in Lung Adenocarcinoma to Improve Prognostic Accuracy and Treatment Efficacy.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Liquid-Liquid Phase Separation (LLPS) refers to the separation of biomacromolecules into separate liquid phases within the cells, plays a critical role in lung cancer pathogenesis. Using machine learning, we developed an LLPS-associated signature (LLPSAS) based on 79 key genes. The LLPSAS demonstrated superior prognostic performance compared to 140 existing lung adenocarcinoma (LUAD) prognostic models. Patients stratified by LLPSAS risk scores revealed significantly lower overall survival in the high-risk group. Comparative analysis between the high-risk and low-risk groups showed distinct pathway enrichment, genomic alterations, tumour immune microenvironment (TIME) profiles, immunotherapy responses and drug sensitivities. The low-risk group exhibited an inflamed TIME, suggesting potentially better immunotherapy response. Furthermore, potential effective small molecule drugs were identified for high-risk patients. Finally, immunohistochemistry confirmed upregulation of LLPS-associated proteins (PLK1, HMMR, PRC1) in LUAD tissues, and immunofluorescence validated their LLPS occurrence. Conclusively, the LLPSAS provides a valuable tool for LUAD prognosis and treatment optimisation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.